Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label study of self-administered subcutaneous icatibant for acute hereditary angioedema attacks
2008-000071-25Phase 3Completed
- Sponsor
- Jerini AG
- Start
- Jul 2009
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of icatibant in hereditary angioedema (HAE), sponsored by Jerini AG. Primary endpoint: Clinical safety with self-treatment of acute hereditary angioedema attacks. Started Jul 2009; status: completed.
02
Drugs
icatibant
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on 2008-000071-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000071-25.